Your browser doesn't support javascript.
Use of antibacterial drugs in 616 COVID-19 patients in Shanghai
Chinese Journal of Nosocomiology ; 30(24):3681-3685, 2020.
Article in English | GIM | ID: covidwho-1318612
ABSTRACT

OBJECTIVE:

To analyze the use of antibiotics in patients with coronavirus disease 2019(COVID-19) in Shanghai and to provide evidence for the treatment of COVID-19 and the management of antibacterial drugs.

METHODS:

The clinical data of 616 patients with COVID-19 in Shanghai Public Health Clinical Center from 20 th, Jan. 2020 to 30 th Apr., 2020 were collected retrospectively, including demographic data, time of admission, time of discharge, and use of antibacterial drugs. All patients were followed up until they were discharged. The frequency of antibacterial drug usage, AUD and the situation of antibacterial using were analyzed.

RESULTS:

Among 616 patients, 137 were mild, 382 were common, 79 were severe and 18 were critical severe. There were 343 males with an average age of 41.1 years and a median length of stay of 16 days, 273 female cases with an average age of 42.8 years and a median length of stay of 14 days. A total of 165 patients(26.8%) received antibiotics therapy. The usage rates of antibiotics in the mild, common, severe and critical severe subgroups were 4.3%, 21.7%, 73.4% and 100.0%, respectively, which was closely related to clinical classification. The overall usage rates of antibacterial drugs in hospitalized patients gradually decreased with the increase of months. In common patients, the usage rates of antibacterial drugs in March and April were significantly lower than that in January and February. The AUD in all patients was 25.3. As the clinical classification worsened, the AUD in each subgroup gradually increased(0.9, 11.9, 46.2, and 143.8). In total, mild and common patients, the AUD showed a downward trend in January, February, March and April. The total frequency of antibacterial drugs was 286 times, and the top 5 most frequently used drugs were fluoroquinolones, beta-lactamase/beta-lactamase inhibitors, carbapenems, cephalosporins, and linezolid. In severe patients, the antibacterial drugs were mainly restricted use grade antibiotics, and in critical severe patients were mainly special use grade antibiotics.

CONCLUSION:

In the treatment of COVID-19 patients, the usage rates of antibacterial drugs and AUD were related to clinical classification. As our knowledge and understanding of COVID-19 deepen, our usage rates and strategies of antibacterial drugs are being adjusted, in order to avoid inappropriate use of antibacterial drugs as much as possible.
Search on Google
Collection: Databases of international organizations Database: GIM Language: English Journal: Chinese Journal of Nosocomiology Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Collection: Databases of international organizations Database: GIM Language: English Journal: Chinese Journal of Nosocomiology Year: 2020 Document Type: Article